معرفی
Professor Jemma Hopewell serves as Professor of Precision Medicine & Epidemiology at the University of Oxford, holding key leadership roles including Senior Scientist in Genetic Epidemiology and Clinical Trials at the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Group leader at the Big Data Institute (BDI), and Principal Investigator for the British Heart Foundation Centre of Research Excellence. She additionally maintains a Visiting Professorship at McGill University's Department of Human Genetics and co-leads the Cardiovascular Medicine Theme at the NIHR Oxford Biomedical Research Centre.
Her academic credentials:
- BSc (Hons)
- MSc
- PhD (University of Cambridge)
Professor Hopewell's research program pioneers the integration of genetic epidemiology, clinical trials, and multi-omics approaches to decipher cardiovascular disease mechanisms and optimize therapeutic strategies. With particular focus on arrhythmias and vascular diseases, her work leverages large-scale genomic and proteomic datasets to investigate drug targets, characterize lipoprotein(a)-mediated risk, and identify predictors of treatment response. Her methodology bridges vascular mega-trials (HPS, REVEAL), biobanks (UK Biobank), and international consortia (CARDIoGRAMplusC4D, METASTROKE) to advance precision medicine frameworks.
Analysis of her recent publications reveals consistent innovation in multi-omics integration for residual risk prediction, with dominant themes spanning atrial fibrillation epidemiology, coronary artery disease genetics across diverse ancestries, stroke subtyping through Mendelian randomization, and pharmacogenetics of lipid-lowering therapies. Her work consistently employs million-participant datasets and novel statistical techniques to address clinical knowledge gaps.
Her scientific recognition includes:
- Fellow of the European Society of Cardiology (FESC)
Professor Hopewell maintains an active mentorship portfolio with four current doctoral students and over a dozen former MSc/DPhil candidates. She secures major research funding as Principal Investigator for the British Heart Foundation Centre of Research Excellence and leads the Clinical Trials Genetics Programme across multiple international studies. Her leadership extends to steering committees of global consortia including METASTROKE and service on grant review panels for the British Heart Foundation and American Heart Association.
She directs the Cardiovascular Precision Medicine research group at Oxford, a multidisciplinary team comprising clinical fellows, medical statisticians, bioinformaticians, and research students. This collaborative environment drives translational research through partnerships with academic institutions and industry to convert genetic epidemiological insights into clinical cardiovascular applications.